直接口服抗凝药颅内出血风险的系统评价与贝叶斯网络Meta分析
该系统评价与贝叶斯网络Meta分析纳入17项随机对照试验共116,618例患者,比较达比加群、利伐沙班、阿哌沙班和依度沙班颅内出血风险。所有直接口服抗凝药颅内出血风险均低于华法林;达比加群110 mg排名最安全(SUCRA 0.85),较利伐沙班降低56%颅内出血风险(OR 0.44,95% Cr.I 0.22-0.82)。
要点
- 所有直接口服抗凝药颅内出血风险均低于华法林(OR 0.46,95% CI 0.35-0.59)。
- 达比加群110 mg排名最安全(SUCRA 0.85),利伐沙班排名最后。
- 达比加群110 mg和150 mg颅内出血风险均低于利伐沙班。
核心结论
- 关于颅内出血风险,达比加群110 mg可能是所有抗凝药中最安全的选择。
- 达比加群110 mg和150 mg的颅内出血风险均低于利伐沙班。
研究设计与样本
- 系统评价与贝叶斯网络Meta分析,检索PubMed/MEDLINE、EMBASE和CENTRAL(起始至2017年12月31日),纳入17项随机对照试验。
- 共纳入116,618例患者:阿哌沙班19,495例、利伐沙班14,157例、达比加群16,074例、依度沙班11,652例、对照药55,315例。
主要发现
- 网络Meta分析中,所有直接口服抗凝药颅内出血风险均低于华法林。
- 达比加群110 mg排名最安全(SUCRA 0.85),较利伐沙班降低56%颅内出血风险(OR 0.44,95% Cr.I 0.22-0.82)。
- 成对Meta分析验证上述结果,直接口服抗凝药较华法林更安全(OR 0.46,95% CI 0.35-0.59)。
- 亚组分析显示,非瓣膜性心房颤动患者使用直接口服抗凝药获益(OR 0.51,95% CI 0.38-0.68),静脉血栓栓塞症患者亦获益(OR 0.32,95% CI 0.18-0.58)。
关键数值与推荐
- 达比加群110 mg较利伐沙班颅内出血风险OR 0.44(95% Cr.I 0.22-0.82),SUCRA 0.85。
- 直接口服抗凝药较华法林颅内出血风险OR 0.46(95% CI 0.35-0.59)。
- 非瓣膜性心房颤动亚组OR 0.51(95% CI 0.38-0.68),静脉血栓栓塞症亚组OR 0.32(95% CI 0.18-0.58)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Risk of intracranial hemorrhage (ICH) may differ between direct oral anticoagulants (DOACs). We compared the risk of ICH between DOACs using network meta-analysis. Dabigatran 110 mg and 150 mg were safer than rivaroxaban on Bayesian analysis. Dabigatran 110 mg ranked as the safest DOAC while rivaroxaban ranked last. SUMMARY: Background The comparative risk of intracranial hemorrhage (ICH) among direct oral anticoagulants (DOACs) (dabigatran, rivaroxaban, apixaban and edoxaban) remains unclear. Objective To determine the difference in risk of ICH between DOACs Methods Seventeen randomized controlled trials (RCTs) were selected using PubMed/MEDLINE, EMBASE and CENTRAL (Inception, 31 December 2017). Estimates were reported as odds ratio (OR) with 95% credible interval (CR.I) in Bayesian network meta-analysis (NMA), and OR with 95% confidence interval (CI) in traditional meta-analyses. Relative ranking probability of each group was generated based on surface under the cumulative ranking curve (SUCRA). Results In NMA of 116 618 patients from 17 RCTs (apixaban = 19 495 patients, rivaroxaban = 14 157 patients, dabigatran = 16 074 patients, edoxaban = 11 652 patients, and comparator = 55 315 patients), all DOACs were safer than warfarin for risk of ICH. Dabigatran 110 mg ranked as the safest drug (SUCRA, 0.85) and reduced the risk of ICH by 56% compared to rivaroxaban (OR, 0.44; 95% Cr.I, 0.22-0.82). Pairwise meta-analysis validated these findings, showing that DOACs were safer than warfarin (OR, 0.46; 95% CI, 0.35-0.59). Subgroup analysis showed that the benefit was present when DOACs were used in non-valvular atrial fibrillation (NVAF) (OR, 0.51; 95% CI, 0.38-0.68) or venous thromboembolism (VTE) (OR, 0.32; 95% CI, 0.18-0.58). Conclusion Dabigatran 110 mg may be the safest choice among any anticoagulant regarding risk of ICH. Both dabigatran 110 mg and 150 mg were safer than rivaroxaban.
引用
- Wolfe Z, Khan SU, Nasir F, et al. A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants. J Thromb Haemost. 2018. PMID: 29723935. doi:10.1111/jth.14131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。